Breaking Down Syndax Pharmaceuticals, Inc. (SNDX) Financial Health: Key Insights for Investors

Are you keeping a close watch on Syndax Pharmaceuticals (SNDX) and trying to decode its financial performance? In 2024, Syndax Pharmaceuticals reported a net loss of $318.8 million, or $3.72 per share. But, the company achieved $7.7 million in net product revenue from Revuforj in its initial five weeks post-launch. With analysts predicting a potential 209.50% increase from the current stock price, is Syndax a promising investment or a risky venture? Let's delve deeper into the numbers and business updates to help you make an informed decision.

Syndax Pharmaceuticals, Inc. (SNDX) Revenue Analysis

Understanding Syndax Pharmaceuticals, Inc.'s revenue streams involves examining its sources, growth, and segment contributions. As a biopharmaceutical company, Syndax's revenue is closely tied to the development and commercialization of its drug candidates.

Syndax Pharmaceuticals, Inc. reported total revenues of $134.8 million for the year ended December 31, 2024, compared to $29.5 million for the year ended December 31, 2023. This represents a substantial year-over-year increase of approximately 357%.

The increase in revenue was primarily driven by:

• Collaboration revenue from agreements with pharmaceutical partners.
• Milestone payments related to the advancement of clinical programs.

A more detailed breakdown reveals the following:

Syndax's revenue streams are heavily influenced by its collaborations and partnerships. These collaborations often involve upfront payments, milestone payments, and royalties on future sales, contingent on the success of their partnered drug candidates. For example, collaboration revenues significantly increased due to the advancement of clinical trials and achievement of specific milestones in 2024.

Significant changes in revenue streams can occur due to various factors:

• New collaboration agreements or modifications to existing ones.
• Clinical trial results impacting the value and progression of drug candidates.
• Regulatory approvals leading to product launches and subsequent sales.

Investors can monitor these developments through Syndax's financial reports, investor presentations, and press releases.

To gain more insight into Syndax Pharmaceuticals, Inc., explore their Mission Statement, Vision, & Core Values of Syndax Pharmaceuticals, Inc. (SNDX).

Syndax Pharmaceuticals, Inc. (SNDX) Profitability Metrics

Assessing the profitability of Syndax Pharmaceuticals, Inc. (SNDX) requires a close examination of its financial statements, focusing on key metrics such as gross profit, operating profit, and net profit margins. These metrics provide insights into the company's efficiency in generating profits from its revenue.

As a biotechnology company, Syndax Pharmaceuticals, Inc.'s profitability profile can differ significantly from other industries. It is important to consider the trends in profitability over time to understand the company's performance and compare its profitability ratios with industry averages to benchmark its success. Analysis of operational efficiency, including cost management and gross margin trends, can offer valuable insights into the company's ability to manage expenses and improve profitability.

According to the Syndax Pharmaceuticals, Inc. 2024 report:

• Research and development expenses were $219.9 million for the year ended December 31, 2024
• Selling, general and administrative expenses were $73.9 million for the year ended December 31, 2024
• Syndax Pharmaceuticals, Inc. reported a net loss of $271.9 million, or $2.08 per share, for the year ended December 31, 2024

Here's a summary of Syndax Pharmaceuticals, Inc.'s financial results for 2024:

Given these figures, Syndax Pharmaceuticals, Inc. is currently operating at a loss. This is not uncommon for biotechnology companies, particularly those heavily invested in research and development. The substantial R&D expenses reflect the company's commitment to developing new therapies, but they also impact the bottom line. The selling, general, and administrative expenses further contribute to the overall financial picture.

To gain more in-depth knowledge about Syndax Pharmaceuticals, Inc. (SNDX) and its investors, check out this link: Exploring Syndax Pharmaceuticals, Inc. (SNDX) Investor Profile: Who’s Buying and Why?

Syndax Pharmaceuticals, Inc. (SNDX) Debt vs. Equity Structure

Understanding Syndax Pharmaceuticals, Inc.'s financial health involves analyzing its approach to debt and equity. This reveals how the company funds its operations and growth.

Syndax Pharmaceuticals, Inc. relies on a mix of debt and equity to finance its operations. As of December 31, 2023, Syndax Pharmaceuticals, Inc. reported the following:

• Total Cash, Cash Equivalents and Short-Term Investments: $338.4 million
• Total Current Liabilities: $37.881 million
• Total Long Term Liabilities: $32.931 million

Syndax Pharmaceuticals, Inc. primarily uses equity financing, which is common for biotech companies that require substantial capital for research and development. However, the company also strategically uses debt to fund specific projects or acquisitions.

Here’s a breakdown of Syndax Pharmaceuticals, Inc.'s debt levels:

• Long-Term Debt: As of December 31, 2023, Syndax Pharmaceuticals, Inc. has $32.931 million in long-term debt.
• Short-Term Debt: The company's short-term liabilities totaled $37.881 million as of December 31, 2023. These short-term obligations consist of accrued expenses and other current liabilities.

The debt-to-equity ratio is a critical metric for evaluating a company's financial leverage. For Syndax Pharmaceuticals, Inc., calculating this ratio using the most recent data provides insights into its risk profile.

The debt-to-equity ratio can be calculated as follows:

Debt-to-Equity Ratio = Total Liabilities / Total Stockholders' Equity

To calculate the debt-to-equity ratio for Syndax Pharmaceuticals, Inc. using their 2023 balance sheet data:

• Total Liabilities = Current Liabilities + Non-Current Liabilities = $37.881 million + $32.931 million = $70.812 million
• Total Stockholders' Equity = $568.794 million
• Debt-to-Equity Ratio = $70.812 million / $568.794 million = 0.1245

A debt-to-equity ratio of 0.1245 indicates that Syndax Pharmaceuticals, Inc. has a relatively low level of debt compared to its equity. This suggests a more conservative financial structure.

Syndax Pharmaceuticals, Inc. has not undertaken any recent significant debt issuances or refinancing activities. The company's financial strategy focuses on:

• Balancing Debt and Equity: Syndax Pharmaceuticals, Inc. balances debt and equity financing to maintain financial flexibility and support its long-term growth objectives.
• Strategic Use of Capital: The company focuses on using its capital for research and development, clinical trials, and potential acquisitions.

More insights about Syndax Pharmaceuticals, Inc. can be found here: Mission Statement, Vision, & Core Values of Syndax Pharmaceuticals, Inc. (SNDX).

Syndax Pharmaceuticals, Inc. (SNDX) Liquidity and Solvency

Assessing liquidity involves examining key financial ratios and statements to understand Syndax Pharmaceuticals, Inc.'s ability to meet its short-term obligations. These metrics provide insights into the company's financial health and its capacity to manage immediate liabilities.

The current ratio and quick ratio are essential indicators of a company's liquidity position. These ratios help to evaluate whether a company has enough liquid assets to cover its short-term liabilities. As of the fiscal year 2024:

• The current ratio, calculated by dividing current assets by current liabilities, offers a view of Syndax Pharmaceuticals, Inc.’s ability to cover its short-term liabilities with its current assets.
• The quick ratio, which excludes inventories from current assets, provides a more conservative measure of liquidity, reflecting the company’s ability to meet its short-term obligations with its most liquid assets.

Analysis of working capital trends is also crucial. Working capital, which is the difference between a company's current assets and current liabilities, indicates the operating liquidity available to a business. Monitoring the trends in working capital can reveal whether Syndax Pharmaceuticals, Inc. is efficiently managing its short-term assets and liabilities. Declining working capital could signal potential liquidity issues, while increasing working capital might indicate improved short-term financial health.

An overview of cash flow statements provides a deeper understanding of Syndax Pharmaceuticals, Inc.’s liquidity. The cash flow statement is divided into three main sections:

• Operating activities: This section shows the cash generated or used from the company's core business operations.
• Investing activities: This includes cash flow from the purchase and sale of long-term assets.
• Financing activities: This section reports cash flow from debt, equity, and dividends.

Reviewing these cash flow trends helps to assess the sustainability of Syndax Pharmaceuticals, Inc.'s cash generation and its ability to fund its operations and investments. Positive cash flow from operating activities is generally a good sign, indicating that the company is generating enough cash from its core business to cover its expenses. Significant cash outflows from investing activities might indicate heavy investments in future growth, while cash inflows from financing activities could mean the company is raising capital through debt or equity.

Potential liquidity concerns or strengths can be identified by analyzing these financial metrics. For example, a high current ratio and quick ratio, coupled with positive cash flow from operating activities, would suggest strong liquidity. Conversely, declining working capital, low liquidity ratios, and negative cash flow from operations could signal potential liquidity risks that need to be addressed.

Here is the data from the most recent 2024 financial year:

For more insights into the company's values, see: Mission Statement, Vision, & Core Values of Syndax Pharmaceuticals, Inc. (SNDX).

Syndax Pharmaceuticals, Inc. (SNDX) Valuation Analysis

Assessing whether Syndax Pharmaceuticals, Inc. (SNDX) is overvalued or undervalued involves examining several key financial metrics and market indicators. These include price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios, stock price trends, and analyst consensus.

Currently, up-to-date specific P/E, P/B, and EV/EBITDA ratios for Syndax Pharmaceuticals, Inc. (SNDX) are not available. These valuation metrics are essential for comparing Syndax Pharmaceuticals, Inc. (SNDX)’s market value to its earnings, book value, and operational cash flow. Without these values, a direct comparison to industry peers or historical data is challenging. Typically, a lower P/E or P/B ratio compared to competitors might suggest undervaluation, while a higher ratio could indicate overvaluation. Similarly, EV/EBITDA helps investors understand if the company's total value is in line with its earnings before interest, taxes, depreciation, and amortization.

Analyzing the stock price trends over the last 12 months provides insights into market sentiment and company performance. As of April 2025, detailed stock performance data, including highs, lows, and average trading prices, can be sourced from financial analysis platforms. These trends can reflect investor confidence, significant company announcements, and broader market conditions. For instance, consistent upward trends might suggest positive market perception, whereas volatility could indicate uncertainty or speculative trading.

Syndax Pharmaceuticals, Inc. (SNDX) does not currently offer a dividend yield, as it is a biotechnology company focused on research and development rather than returning profits to shareholders through dividends. Therefore, dividend payout ratios are not applicable.

Analyst consensus on Syndax Pharmaceuticals, Inc. (SNDX) stock valuation is crucial for gauging market expectations. Recent ratings typically range from buy to hold or sell, reflecting diverse opinions on the stock's potential. For example:

• As of April 18, 2025, HC Wainwright & Co. reiterated a Buy rating with a price target of $34.00.
• On April 16, 2025, Wedbush maintained an Outperform rating and a price target of $33.00.
• On April 9, 2025, Oppenheimer reaffirmed an Outperform rating with a price target of $38.00.

These ratings suggest a generally positive outlook from analysts, though individual investment decisions should be based on a comprehensive analysis of available data and personal risk tolerance.

For more detailed information, you can refer to: Breaking Down Syndax Pharmaceuticals, Inc. (SNDX) Financial Health: Key Insights for Investors

Syndax Pharmaceuticals, Inc. (SNDX) Risk Factors

Syndax Pharmaceuticals, Inc. (SNDX) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges and external market dynamics, including industry competition, regulatory changes, and overall market conditions.

Here's a breakdown of key risk areas:

• Industry Competition: The biotechnology industry is intensely competitive. Syndax faces competition from other pharmaceutical companies, biotechnology firms, and academic institutions, all vying to develop and market innovative therapies. Newer entrants and established giants alike pose a threat.
• Regulatory Changes: The development, approval, and marketing of pharmaceutical products are heavily regulated. Changes in regulations by the FDA or other regulatory bodies can significantly impact Syndax's ability to bring products to market, potentially delaying approvals or increasing costs.
• Market Conditions: Broader economic and market conditions can influence Syndax's financial performance. Economic downturns, changes in healthcare spending, or shifts in investor sentiment towards the biotechnology sector can all create headwinds.

Operational, financial, and strategic risks are often detailed in Syndax's earnings reports and filings. These may include:

• Clinical Trial Risks: The success of Syndax heavily relies on the outcomes of its clinical trials. Unfavorable results, delays, or safety concerns in these trials can lead to significant setbacks, impacting the company’s pipeline and future revenue potential.
• Manufacturing and Supply Chain Risks: Syndax depends on third-party manufacturers for its drug supply. Disruptions to the supply chain, manufacturing issues, or quality control problems can affect the availability of its products and increase costs.
• Commercialization Risks: Even with regulatory approval, the successful commercialization of Syndax's products is not guaranteed. Factors such as market acceptance, pricing pressures, and competition can influence the uptake of their therapies.
• Financial Risks: Managing cash flow, securing additional funding, and effectively allocating capital are critical. Unexpected expenses, lower-than-anticipated revenues, or difficulties in raising capital could strain the company’s financial resources.

While specific mitigation strategies can vary, Syndax likely employs several approaches to manage these risks:

• Diversification of Pipeline: Developing a diverse portfolio of drug candidates can reduce the company’s reliance on any single product.
• Strategic Partnerships: Collaborating with other companies can share the risks and costs associated with drug development and commercialization.
• Robust Clinical Trial Design: Implementing well-designed clinical trials with clear endpoints can increase the likelihood of success.
• Proactive Regulatory Engagement: Maintaining open communication with regulatory agencies can help navigate the approval process and address potential concerns.
• Careful Financial Planning: Implementing sound financial management practices, including cost control measures and proactive fundraising, can help ensure the company’s financial stability.

For more insights into Syndax Pharmaceuticals, Inc. (SNDX), check out: Exploring Syndax Pharmaceuticals, Inc. (SNDX) Investor Profile: Who’s Buying and Why?

Syndax Pharmaceuticals, Inc. (SNDX) Growth Opportunities

Syndax Pharmaceuticals, Inc. (SNDX) is strategically positioned for future growth, driven by several key factors. These include product innovations, potential market expansions, strategic initiatives, and competitive advantages.

Key growth drivers for Syndax Pharmaceuticals, Inc. (SNDX) include:

• Product Innovations: Development and commercialization of new therapies.
• Market Expansions: Extending the reach of existing products into new geographic markets or patient populations.
• Strategic Initiatives: Leveraging partnerships and collaborations to enhance research and development efforts.

Future revenue growth projections and earnings estimates for Syndax Pharmaceuticals, Inc. (SNDX) are contingent upon successful clinical trials and regulatory approvals. Keep an eye on Mission Statement, Vision, & Core Values of Syndax Pharmaceuticals, Inc. (SNDX).

Strategic initiatives and partnerships that may drive future growth:

• Collaborations: Partnering with other pharmaceutical companies or research institutions to accelerate drug development.
• Licensing Agreements: Acquiring rights to promising drug candidates or technologies.

Syndax Pharmaceuticals, Inc. (SNDX) possesses several competitive advantages that could position the company for growth:

• Innovative Pipeline: A diverse portfolio of drug candidates targeting unmet medical needs.
• Strategic Partnerships: Collaborations with leading research institutions and pharmaceutical companies.

The success of Syndax Pharmaceuticals, Inc. (SNDX) depends on various factors, including clinical trial outcomes, regulatory approvals, and market dynamics. Investors should closely monitor these developments to assess the company's growth potential.